SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SCYX
SCYNEXIS, Inc. (SCYX) EV/Sales
As of 16 October 2026, SCYNEXIS, Inc. (SCYX) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from −64.5× (December 2018) to 509× (January 2015); the current reading is higher than 20% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | (87.31%) |
| FY2024 | 6.6× | 2,033.92% |
| FY2023 | 0.3× | (95.97%) |
| FY2022 | 7.7× | 4.76% |
| FY2021 | 7.4× | (90.34%) |
| FY2019 | 76.2× | — |
| FY2018 | −2.4× | — |
| FY2017 | 123× | (10.29%) |
| FY2016 | 138× | (18.82%) |
| FY2015 | 170× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 14.49% |
| Dec 2025 | 0.8× | (90.61%) |
| Sep 2025 | 9.0× | 101.15% |
| Jun 2025 | 4.5× | (63.28%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −19.9× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| INCR InterCure Ltd. compare | 0.7× |
| SCYX SCYNEXIS, Inc. | 0.7× |
| CPHI China Pharma Holdings, Inc. compare | 8.1× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| TLPH Talphera, Inc. compare | 166× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)